Retatrutide heart rate increase is an important safety consideration for this investigational triple agonist, which simultaneously targets GLP-1, GIP, and glucagon receptors. Unlike approved agents such as semaglutide or tirzepatide, retatrutide's broader receptor activity — particularly its glucagon component — may produce a more pronounced chronotropic effect. Phase 2 clinical trial data published in 2023 documented dose-dependent rises in resting heart rate, raising questions about cardiac monitoring, risk stratification, and management. This article explains the mechanism, trial evidence, at-risk groups, and what patients and clinicians should do if a significant heart rate elevation occurs.

How Retatrutide Affects Heart Rate

Retatrutide increases resting heart rate primarily through GLP-1 receptor-mediated chronotropic effects at the sinoatrial node, potentially amplified by its glucagon receptor agonism, which independently raises heart rate and cardiac contractility.

Retatrutide is an investigational triple agonist that simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor activity distinguishes it from existing approved agents such as semaglutide and tirzepatide, and it is this broader pharmacological profile that is thought to contribute to its cardiovascular effects, including an increase in resting heart rate.

The GLP-1 receptor component is hypothesised to play a significant role in the observed rise in heart rate. GLP-1 receptors are expressed in cardiac tissue and the sinoatrial node, and their activation is thought to produce a modest but measurable chronotropic effect — meaning the heart may be stimulated to beat faster. The precise mechanism in humans remains incompletely understood and is based partly on extrapolation from preclinical data and from clinical observations with approved GLP-1 receptor agonists. Similar increases in resting heart rate have been documented with liraglutide (Saxenda) and semaglutide (Wegovy/Ozempic), as noted in their respective UK Summaries of Product Characteristics (SmPCs) available via the Electronic Medicines Compendium (eMC).

The glucagon receptor agonism present in retatrutide may further amplify this effect. Glucagon is known to have positive chronotropic and inotropic properties, meaning it can increase both heart rate and the force of cardiac contractions. It is plausible, though not yet proven specifically for retatrutide, that combined stimulation of GLP-1 and glucagon receptors could produce a more pronounced elevation in heart rate compared with single or dual agonists. This remains an important pharmacological consideration as retatrutide progresses through clinical development, and mechanistic conclusions should be regarded as provisional pending further evidence.

What the Clinical Trial Evidence Shows

Phase 2 trials published in NEJM (2023) reported dose-dependent mean resting heart rate increases of approximately 5–7 bpm at higher doses; these elevations were not associated with serious cardiac events, but Phase 3 data are needed.

The most significant clinical data on retatrutide to date come from its Phase 2 trials, published in the New England Journal of Medicine in 2023. These trials evaluated retatrutide across a range of doses in adults with obesity or type 2 diabetes. Alongside substantial weight reductions — with some participants losing over 24% of body weight at higher doses — the trials also documented a dose-dependent increase in resting heart rate.

Participants receiving higher doses of retatrutide (particularly 8 mg and 12 mg weekly) experienced mean increases in heart rate of approximately 5 to 7 beats per minute (bpm) above baseline, based on data reported in the 2023 NEJM Phase 2 publications. This elevation was generally observed early in treatment and appeared to plateau over time rather than continuing to rise progressively, though this observation should be regarded as exploratory given the trial design. The increases were broadly consistent with those documented for approved GLP-1 receptor agonists in their respective SmPCs.

It is important to note that Phase 2 trials typically exclude participants with significant cardiovascular disease, which limits the generalisability of these safety findings to higher-risk populations. Whilst the heart rate increases observed were statistically significant, they were not associated with a higher rate of serious adverse cardiac events in the Phase 2 data. However, Phase 2 trials are not powered to detect rare cardiovascular outcomes, and longer-term Phase 3 data — including dedicated cardiovascular outcome trials — will be essential to fully characterise the cardiac safety profile of retatrutide. As of the time of writing, retatrutide has not received approval from the MHRA or EMA, and its full safety profile remains under investigation.

Who Is Most at Risk of This Side Effect

Individuals with pre-existing tachycardia, arrhythmias, hyperthyroidism, or heart failure, and those taking sympathomimetics or SNRIs, are most likely to require closer cardiac monitoring during retatrutide treatment.

Not all individuals are equally susceptible to heart rate increases associated with GLP-1-based therapies. Based on class effects observed with approved agents and general clinical reasoning, certain patient groups may warrant closer monitoring during any future clinical use of retatrutide. The following risk groups are identified by extrapolation from comparator SmPCs and clinical principles, rather than from retatrutide-specific evidence.

Those who may warrant closer monitoring include:

• Individuals with pre-existing tachycardia or arrhythmias, such as atrial fibrillation or supraventricular tachycardia

• Patients with hyperthyroidism, which independently elevates resting heart rate

• Those taking other medicines that may increase heart rate, including sympathomimetics (such as decongestants and stimulants), serotonin–noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants, or beta-2 agonists used in asthma management

• Individuals with a history of heart failure, where even modest increases in heart rate may affect cardiac output and symptom burden — though it should be noted that increased cardiovascular risk in this group is based on clinical prudence rather than confirmed harm with GLP-1 receptor agonists

• Patients receiving higher doses of retatrutide, given the dose-dependent nature of the effect observed in Phase 2 trials

Age and baseline cardiovascular health are also relevant considerations. Older adults and those with established cardiovascular disease may have less physiological reserve to accommodate sustained increases in heart rate. Additionally, dehydration — which can occur secondary to the gastrointestinal side effects of GLP-1-based therapies, such as nausea and vomiting — may compound the chronotropic effect by triggering a compensatory reflex tachycardia. Clinicians should take a thorough cardiovascular history and record a baseline heart rate before initiating treatment, and reassess regularly throughout the course of therapy.

When to Seek Medical Advice

Seek medical advice if you develop a persistent resting heart rate above 100 bpm, palpitations, dizziness, or chest discomfort; call 999 or go to A&E for chest pain, collapse, or a very rapid irregular heartbeat.

Patients and healthcare professionals should be aware of the symptoms that may indicate a clinically significant increase in heart rate during retatrutide treatment. Whilst a mild, asymptomatic rise in resting heart rate is generally considered an expected pharmacological effect of GLP-1-based therapies, certain presentations should prompt timely medical review.

Contact your GP, healthcare provider, or — if you need urgent advice — NHS 111 if you experience:

• A persistent resting heart rate above 100 bpm (resting tachycardia)

• Palpitations — a sensation of a racing, fluttering, or pounding heartbeat

• Dizziness, light-headedness, or near-fainting episodes

• Chest discomfort or tightness, particularly if associated with exertion

• Shortness of breath that is new or worsening

• Fatigue that is disproportionate to your level of activity

Seek emergency medical attention (call 999 or go to A&E) if you experience:

• Chest pain radiating to the arm, jaw, or back

• Sudden severe breathlessness

• Loss of consciousness or collapse

• A very rapid or irregular heartbeat that does not settle within a few minutes

Some symptoms, such as mild palpitations or a sensation of a faster heartbeat, may be transient and occur particularly after dose escalation. However, any symptom that is persistent, severe, or accompanied by other warning signs should not be self-managed without professional assessment.

If you are participating in a clinical trial involving retatrutide, you should also contact your research team or trial investigator promptly if you experience any of the above symptoms, in accordance with the trial protocol.

Patients and healthcare professionals are encouraged to report suspected side effects of any medicine — including those experienced in clinical trials — via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps the MHRA monitor the safety of medicines in the UK.

Managing an Elevated Heart Rate During Treatment

Management of elevated heart rate during retatrutide treatment includes dose review, medication review, ensuring adequate hydration, and — if tachycardia persists — specialist referral or discontinuation, always in agreement with the trial investigator.

If a clinically meaningful increase in heart rate is identified during retatrutide treatment, several management strategies may be considered, depending on the severity of the elevation and the presence of associated symptoms. Because retatrutide remains an investigational medicinal product, any changes to dosing or treatment must be agreed with the trial investigator and undertaken in accordance with the clinical trial protocol. Management should always be guided by a qualified healthcare professional.

For mild, asymptomatic increases in heart rate, a period of watchful waiting with regular monitoring may be appropriate. Clinicians should record baseline heart rate before initiating treatment and reassess at each follow-up appointment. This approach is consistent with monitoring advice provided in the SmPCs of approved comparator agents such as liraglutide (Saxenda) and semaglutide (Wegovy), which advise awareness of heart rate changes during treatment. Ensuring adequate hydration is an important and often overlooked step, as dehydration secondary to gastrointestinal side effects can exacerbate tachycardia.

Practical management considerations include:

• Dose review: If the heart rate increase is dose-dependent and symptomatic, reducing the dose or slowing the titration schedule — where permitted by the trial protocol — may help mitigate the effect whilst preserving therapeutic benefit. The liraglutide SmPC, for example, advises considering discontinuation if a clinically relevant sustained increase in resting heart rate is observed.

• Medication review: A thorough review of concomitant medicines that may independently raise heart rate is advisable, including sympathomimetics, SNRIs, tricyclic antidepressants, and beta-2 agonists

• Lifestyle measures: Reducing caffeine intake, managing stress, and ensuring adequate sleep can all contribute to heart rate regulation

• Cardiac monitoring: In patients with pre-existing cardiac conditions, an electrocardiogram (ECG) or ambulatory heart rate monitoring may be warranted

• Specialist referral: If tachycardia persists or is associated with arrhythmia, referral to a cardiologist should be considered

In some cases, if the heart rate elevation is persistent and symptomatic despite dose adjustment, discontinuation of retatrutide may be necessary. Any decision to stop treatment must be made collaboratively between the patient, their clinical team, and — given the investigational context — the trial investigator, weighing the cardiovascular risk against the metabolic benefits of continued therapy.

Regulatory Status and Current Safety Considerations

Retatrutide holds no MHRA or EMA marketing authorisation and is available only within authorised clinical trials; heart rate monitoring guidance is currently extrapolated from approved GLP-1 receptor agonist SmPCs such as liraglutide and semaglutide.

As of the time of writing, retatrutide has not been granted a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It therefore remains an investigational medicinal product, available only within the context of authorised clinical trials. There is currently no MHRA Summary of Product Characteristics (SmPC), formal prescribing guidance, or MHRA Drug Safety Update specific to retatrutide in the United Kingdom.

Guidance on heart rate monitoring in the context of GLP-1-based therapies is currently derived from the SmPCs of approved comparator agents. For example, the UK SmPCs for liraglutide (Saxenda) and semaglutide (Wegovy/Ozempic), available via the Electronic Medicines Compendium (eMC), advise awareness of heart rate increases during treatment and recommend that clinicians consider discontinuation if a clinically relevant sustained rise in resting heart rate is observed. The SmPC for tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, similarly documents modest mean heart rate increases. These product-level recommendations provide a relevant framework for clinical vigilance, but should not be assumed to apply directly to retatrutide until its own regulatory documentation is available.

NICE has not yet issued technology appraisal guidance or clinical guidelines specific to retatrutide, given its investigational status. However, existing NICE guidance on the management of obesity and type 2 diabetes — including guidance on approved GLP-1 receptor agonists — provides a relevant framework for understanding how such agents are evaluated and monitored within the NHS.

Patients and healthcare professionals are reminded to report any suspected adverse reactions to medicines, including those experienced within clinical trials, via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

It is important to emphasise that individuals should not attempt to obtain retatrutide outside of authorised clinical trial settings. The use of unlicensed or unregulated weight-loss medicines carries significant safety risks; the MHRA has issued advice on the dangers of purchasing medicines from unregulated sources. Patients interested in participating in clinical trials involving retatrutide should speak with their GP or specialist, who can advise on eligibility and refer to appropriate research centres. Ongoing Phase 3 trial data will be critical in informing future regulatory decisions and clinical guidance.

Frequently Asked Questions